We’d like to remind Interim readers that the last opportunity to make known opposition to the reclassification of the so-called morning-after pill is almost here. In May, the Health Canada agency announced its intentions to allow the drug, formally known as levonorgestrel, to be available over-the-counter at pharmacies without a doctor’s prescription.
Pro-life advocates have been opposing this reclassification on a number of grounds, especially because of the fact that at least in some cases – and despite claims to the contrary – the drug causes an early abortion. It prevents a newly created human being from implanting in his or her mother’s uterus and continuing the path toward birth.
As well, there are concerns over the effects on women ingesting it, the lack of supervision over young people who may be exposed to it and the potential for it to encourage more sexual promiscuity out of the misguide notion that there is a “backup” available if something goes wrong.
Submissions on the matter can be sent, by August 5, to: Karen Ash, Policy Division, Bureau of Policy, Therapeutic Products Directorate, Department of Health, Address Locator 3102C5, 1600 Scott St., Holland Cross, Tower B, 2nd Floor, Ottawa, Ont., K1A 0K9. Tel: (613) 957-6455
